Shattuck Labs Announces Two Poster Presentations at UEG Week 2026

Shattuck Labs (STTK) announced two upcoming poster presentations at United European Gastroenterology Week 2026, taking place October 17–20 in Barcelona, Spain.

Rhea-AI Summary

Shattuck Labs (STTK) announced two upcoming poster presentations at United European Gastroenterology Week 2026, taking place October 17–20 in Barcelona, Spain.

A moderated poster on the development and characterization of SL-846 is scheduled for October 19. An ePoster on TL1A immune complexes and anti-drug antibodies will be available throughout the congress. Both posters will be posted on the company’s website following the congress.

Argus Oct 13 session 40 alerts

-10.10% close to close 2.1x rel. volume Open Argus

Details

News Market Reaction – STTK

-6.2% Trough in 4 hr 31 min

$586.12M Market Cap

On Oct 13, the day this news came out, STTK closed 10.10% below the previous close. Argus tracked a trough of -6.2% from its starting point during tracking. Our momentum scanner recorded 40 alerts for this stock that day. Relative volume reached 2.1x the daily average during tracking.

Data tracked by StockTitan Argus for the Oct 13 session.

Key Terms

bispecific antibody, immune complexes, anti-drug antibodies

3 terms

bispecific antibody medical

"Development and Characterization of SL-846: A Half-Life Extended, Dual-Receptor (DR3 x IL23RA) Targeting Bispecific Antibody"

A bispecific antibody is a specially designed protein that can attach to two different targets at the same time. Think of it as a custom-made connector that brings two things together—such as a disease cell and an immune system component—helping the body fight illnesses more effectively. For investors, understanding bispecific antibodies is important because they represent innovative therapies that could lead to new treatments and potentially lucrative market opportunities.

immune complexes medical

"Soluble TL1A/Anti-TL1A Immune Complexes Induce De Novo Production of TL1A"

Collections formed when antibodies bind to their specific target molecules (antigens), creating antibody–antigen aggregates that can circulate in blood or deposit in tissues; their formation is a normal part of clearing infections but can also trigger inflammation by activating the complement system and recruiting immune cells. Size, composition, and where they accumulate determine whether they are quickly removed by the spleen and liver or persist and cause immune-mediated tissue injury (for example in some autoimmune reactions or hypersensitivity responses).

anti-drug antibodies medical

"and Induce Anti-Drug Antibodies That Cross-Bind Approved IBD Antibodies"

Anti-drug antibodies are immune system proteins that form in patients in response to a biological therapy, such as a therapeutic protein or antibody, and can bind to the medicine. They matter to investors because they can reduce or eliminate a drug’s effectiveness, create safety problems, force higher dosing or additional testing, and influence regulatory approval and commercial success — like delivery guards accidentally intercepting and stopping a needed package.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

AUSTIN, Texas and DURHAM, N.C., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potential first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced two upcoming poster presentations at United European Gastroenterology (UEG) Week 2026, taking place October 17–20, 2026, in Barcelona, Spain.

Presentation Details

Format: Moderated poster presentation
Title: Development and Characterization of SL-846: A Half-Life Extended, Dual-Receptor (DR3 x IL23RA) Targeting Bispecific Antibody
Presenter: Mahmud Hussain, Ph.D., Director, R&D of Shattuck Labs
Date/Time: October 19, 2026; 1:00–2:00 p.m. CEST

Format: ePoster presentation
Title: Soluble TL1A/Anti-TL1A Immune Complexes Induce De Novo Production of TL1A and Induce Anti-Drug Antibodies That Cross-Bind Approved IBD Antibodies
Presenter: Suresh de Silva, Ph.D., Chief Scientific Officer of Shattuck Labs
Date/Time: October 17–20, 2026 (available for viewing throughout the congress)

The posters will be available under Events & Presentations in the Investor Relations section of the Company’s website at www.shattucklabs.com following the congress.

About Shattuck Labs, Inc.
Shattuck Labs, Inc. is a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases. Shattuck’s expertise in protein engineering and the development of novel TNF receptor therapeutics come together in its lead program, SL-325, a potentially first-in-class DR3 antagonist antibody designed to achieve a more complete blockade of the clinically validated DR3/TL1A pathway. The Company has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.

Investor & Media Contact:
Andrew R. Neill
Chief Financial Officer
Shattuck Labs, Inc.
InvestorRelations@shattucklabs.com